AIM ImmunoTech logo
AIM ImmunoTech AIM
$ 0.81 -0.01%

Quarterly report 2025-Q3
added 11-17-2025

report update icon

AIM ImmunoTech Cash Flow 2011-2026 | AIM

Annual Cash Flow AIM ImmunoTech

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-16.1 M -14 M -10.4 M -9.07 M -10.6 M -7.94 M -7.38 M -16.1 M -14 M -16.8 M -13.1 M -10.1 M

Depreciation & Amortization

38 K 659 K 665 K 735 K 856 K 948 K 1.12 M 941 K 665 K 671 K 643 K 465 K

Accounts Payables

377 K 198 K 383 K 472 K 680 K 741 K 887 K 1.21 M 2.08 M 1.27 M 2.16 M 1.68 M

Accounts Receivables

- - 34 K 44 K 235 K 24 K - - - - - -

All numbers in USD currency

Quarterly Cash Flow AIM ImmunoTech

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -2.36 M - - - -4.82 M - - - -3.68 M - -10 M -5.07 M -2.76 M - -8.22 M -4.76 M -3.04 M - -7.51 M -4.52 M -3.25 M - -6.78 M -4.23 M -1.46 M - -8.22 M -5.24 M -2.54 M - -7.18 M -5.3 M -2.99 M - -5.28 M -2.29 M -1.04 M - - - -4.26 M - -9.93 M -6.21 M -2.9 M - -13.6 M -9.63 M -5.85 M - -8.18 M -5.48 M -1.66 M - -7.07 M -4.8 M -1.82 M

Depreciation & Amortization

- - 10 K - - - 9 K - - - 11 K - 29 K 20 K 10 K - 484 K 325 K 162 K - 500 K 340 K 173 K - 557 K 380 K 194 K - 658 K 444 K 216 K - 739 K 504 K 261 K - 854 K 576 K 300 K - 663 K 458 K 180 K - 500 K 332 K 167 K - 504 K 350 K 179 K - 469 K 296 K 149 K - 322 K 198 K 112 K

Accounts Payables

1.25 M 7.3 M 6.94 M 6.38 M 6.26 M 5.46 M 6.57 M 6.44 M 2.79 M 2.15 M - 377 K 957 K 712 K 378 K 198 K 369 K 451 K 189 K 383 K 383 K 383 K 383 K 472 K 472 K 472 K 472 K 680 K 680 K 680 K 680 K 741 K 741 K 741 K 741 K 887 K 887 K 887 K 887 K 1.21 M 1.21 M 1.21 M 1.21 M 2.08 M 2.08 M 2.08 M 2.08 M 1.27 M 1.27 M 1.27 M 1.27 M 2.16 M 2.16 M 2.16 M 2.16 M 1.68 M 1.68 M 1.68 M 1.68 M

Accounts Receivables

- - - - - - - 1.18 M 48 K 33 K - 1.68 M - - - - 28 K 28 K 34 K 34 K 34 K 34 K 34 K 44 K 44 K 44 K 44 K 235 K 235 K 235 K 235 K 24 K 24 K 24 K 24 K - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company AIM ImmunoTech, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
argenx SE argenx SE
ARGX
$ 843.68 1.22 % $ 25 B niderlandNiderland
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 4.13 5.36 % $ 352 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Adagene Adagene
ADAG
$ 3.19 11.93 % $ 180 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.71 -16.82 % $ 3.87 M chinaChina
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Biogen Biogen
BIIB
$ 197.56 1.05 % $ 28.9 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.47 -1.12 % $ 8.35 B australiaAustralia
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 60.75 1.49 % $ 124 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 107.57 1.76 % $ 27.2 B germanyGermany
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 219.1 0.46 % $ 5 B danmarkDanmark
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 40.16 4.73 % $ 4.15 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.42 2.9 % $ 362 M britainBritain
Burford Capital Limited Burford Capital Limited
BUR
$ 9.38 0.86 % $ 1.5 B britainBritain
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.91 1.92 % $ 4.61 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 53.36 9.05 % $ 4.8 B schweizSchweiz
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany